Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Low Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06733233
What this trial is testing

A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

Who this might be right for
Breast Cancer, Estrogen Receptor-PositiveHER2 Low Breast Cancer
Guangzhou Women and Children's Medical Center 23
Testing effectiveness (Phase 2)UnknownNCT02829008
What this trial is testing

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

Who this might be right for
Metastatic Breast Cancer
Chinese Academy of Medical Sciences 120
Not applicableStudy completedNCT05754047
What this trial is testing

Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients

Who this might be right for
HER2 Low Breast Carcinoma
Mahdis Bayat 3,582
Testing effectiveness (Phase 2)Ended earlyNCT05163223
What this trial is testing

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Who this might be right for
Breast Cancer
Aston Sci. Inc. 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT06048718
What this trial is testing

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases

Who this might be right for
Breast CancerMetastatic Breast Cancer
MedSIR 28
Testing effectiveness (Phase 2)Looking for participantsNCT05868226
What this trial is testing

PRE-ISPY Phase I/II Oncology Platform Program

Who this might be right for
HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more
QuantumLeap Healthcare Collaborative 280
Testing effectiveness (Phase 2)Looking for participantsNCT05704829
What this trial is testing

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

Who this might be right for
HER2-positive Early Breast Cancer
Women's Cancer Study Group GmbH 702
Not applicableStudy completedNCT06363812
What this trial is testing

Probability of OncotypeDx to Reallocate As Low or High Risk of Recurrence Breast Cancer Patients with Uncertain Biology

Who this might be right for
Breast Cancer
Fondazione Sandro Pitigliani 258
Not applicableEnded earlyNCT06231693
What this trial is testing

Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

Who this might be right for
Breast Cancer
AstraZeneca 2
Not applicableStudy completedNCT07108595
What this trial is testing

Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 142
Large-scale testing (Phase 3)Active Not RecruitingNCT05705401
What this trial is testing

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
NRG Oncology 1,300
Testing effectiveness (Phase 2)Looking for participantsNCT06953882
What this trial is testing

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Who this might be right for
HER2 Negative Breast Cancer
Yale University 140
Early research (Phase 1)Active Not RecruitingNCT05633979
What this trial is testing

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 17
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06547476
What this trial is testing

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Who this might be right for
Breast Cancer
Guangdong Provincial People's Hospital 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT05824325
What this trial is testing

Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）

Who this might be right for
Breast Cancer
Fudan University 56
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06680596
What this trial is testing

Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

Who this might be right for
Breast Cancer MetastaticBreast Cancer Stage IV
UNICANCER 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT06008158
What this trial is testing

Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca

Who this might be right for
Anatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Estrogen Receptor-Positive Breast Carcinoma+1 more
City of Hope Medical Center 48
Testing effectiveness (Phase 2)Looking for participantsNCT07498478
What this trial is testing

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Who this might be right for
Breast Cancer
TransThera Sciences (Nanjing), Inc. 94
Testing effectiveness (Phase 2)WithdrawnNCT05967286
What this trial is testing

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast Carcinoma+1 more
National Cancer Institute (NCI)
Early research (Phase 1)Ended earlyNCT05514717
What this trial is testing

XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Non-Small Cell Lung Cancer+3 more
Day One Biopharmaceuticals, Inc. 57
Next Page